Skip to content
  • Home
  • News
  • About Us
    • Mission & Vision
    • Message from the CEO
    • Company Profile
    • Members
    • Access
  • Science & Technology
    • What Are Diabetes Stem Cells?
    • Complete Remission of Diabetes.
    • What Is Biozipcode™?
    • Cell-Targeting Technology
    • Academic Collaboration Overview
      • Dep. of Biocommunication Development (Kyoto Univ)
      • Domestic & Inter. Research Collaborations
    • Pipeline Overview
      • Diabetes Remission Therapy Candidate
      • Diabetes Stem Cell Biomarker
      • Biozipcode™ Cell-Targeted Diabetes Therapy
      • Cell-Targeted Oncology Therapeutics
      • Cell-Targeted Tissue Regeneration
    • Research Achievements
      • Selected Publications
      • Patents & Intellectual Property
      • Videos, Lectures & Presentations
  • For Partners
    • For Pharmaceutical Com. & Research Instit.
    • Research Collaboration
    • Technology Licensing
    • Co-development
    • Investment & Strategic Partnerships
    • Downloads
  • Contact
    • Contact Form
    • Legal & Policies
    • Privacy Policy
    • Website Policy
    • Cookie Policy
    • Medical & Scientific Disclaimer
    • Conflict of Interest & Transparency Policy
JapaneseJapanese

All News

All News

All Newsbiozipadmin2026-09-26T13:21:39+09:00
  • News

    Announcement of the Relocation of the Department of Biocommunication Development to Kyoto University and the Launch of Joint Industry–Academia Research

    Announcement of the Relocation of the Department of Biocommunication Development to Kyoto University and the Launch of Joint Industry–Academia Research

    2026-04-01
  • ニュース

    2022-09-12

    会社株式会社バイオジップコード「BioJapan2022」に出展

    Read Article
  • News

    2022-09-01

    Announcement of a Seminar by Hideto Kojima, Head of Research and Development at Biozipcode, Inc. — “Say Goodbye to Diabetes!”

    Read Article
  • ニュース

    2022-09-01

    株式会社バイオジップコード 研究開発責任者小島秀人氏のセミナー開催のお知らせ ~「糖尿病にさようなら!」~

    Read Article
  • News

    2022-04-18

    Biozipcode, Inc. Announces Acquisition of Rights Related to International Patent Applications for Diabetes Treatments

    Read Article
  • News

    2022-01-01

    Launch of the Biozipcode, Inc. Website

    Read Article
Previous12
Important Notice on Medical & Research Information
IMPORTANT NOTICE

Important Notice on Medical & Research Information

Important Notice on Medical & Research Information

This site introduces research and development conducted by Biozipcode, Inc. and its research collaborators. It does not provide diagnosis, treatment, or medical advice for individual patients.

The research findings presented here include basic and preclinical studies using cells, animal models, and research specimens. Results in animal models do not establish efficacy or safety in humans. Terms such as “complete remission,” “curative treatment,” and “diabetes stem cells (DSCs)” include research concepts and development goals that remain to be tested. Diabetes stem cells is a term used in this research, not an established clinical diagnosis.

Medical & Scientific DisclaimerMedical & Scientific Disclaimer

Biozipcode, Inc.

2F-C, Shibuya Dogenzaka Tokyu Building, 1-10-8 Dogenzaka, Shibuya-ku, Tokyo 150-0043, Japan

+81-03-6821-7318+81-03-6821-7318
Contact UsContact Us
  • Home
  • News
  • About Us
  • Mission & Vision
  • Message from the CEO
  • Company Profile
  • Members
  • Access
  • Research Achievements
  • Selected Publications
  • Patents & Intellectual Property
  • Videos, Lectures & Presentations
  • Science & Technology
  • What Are Diabetes Stem Cells?
  • Complete Remission of Diabetes and Elimination of Diabetes Stem Cells
  • What Is Biozipcode™?
  • Cell-Targeting Technology
  • Pipeline Overview
  • Diabetes Remission Therapy Candidate
  • Diabetes Stem Cell Biomarker
  • Biozipcode™ Cell-Targeted Diabetes Therapy
  • Cell-Targeted Oncology Therapeutics
  • Cell-Targeted Tissue Regeneration
  • Department of Biocommunication Development
  • Academic Collaboration
  • Department of Biocommunication Development
  • Domestic and International Research Collaborations
  • For Partners
  • For Pharmaceutical Companies & Research Institutions
  • Research Collaboration
  • Technology Licensing
  • Co-development
  • Investment & Strategic Partnerships
  • Downloads
  • Contact
  • Legal & Policies
  • Privacy Policy
  • Website Policy
  • Cookie Policy
  • Medical & Scientific Disclaimer
  • Conflict of Interest & Transparency Policy

© Copyright 2023 - 2026 | Biozipcode, Inc. All Rights Reserved.

Japanese / English

Page load link

Biozipcode, Inc.

  • Home
  • News
  • About Us
    • Mission & Vision
    • Message from the CEO
    • Company Profile
    • Members
    • Access
  • Science & Technology
    • What Are Diabetes Stem Cells?
    • Complete Remission of Diabetes.
    • What Is Biozipcode™?
    • Cell-Targeting Technology
    • Academic Collaboration Overview
      • Dep. of Biocommunication Development (Kyoto Univ)
      • Domestic & Inter. Research Collaborations
    • Pipeline Overview
      • Diabetes Remission Therapy Candidate
      • Diabetes Stem Cell Biomarker
      • Biozipcode™ Cell-Targeted Diabetes Therapy
      • Cell-Targeted Oncology Therapeutics
      • Cell-Targeted Tissue Regeneration
    • Research Achievements
      • Selected Publications
      • Patents & Intellectual Property
      • Videos, Lectures & Presentations
  • For Partners
    • For Pharmaceutical Com. & Research Instit.
    • Research Collaboration
    • Technology Licensing
    • Co-development
    • Investment & Strategic Partnerships
    • Downloads
  • Contact
    • Contact Form
    • Legal & Policies
    • Privacy Policy
    • Website Policy
    • Cookie Policy
    • Medical & Scientific Disclaimer
    • Conflict of Interest & Transparency Policy

Biozipcode, Inc.
株式会社バイオジップコード

  • ホーム
  • ニュース
  • 私たちについて
    • ミッション・ビジョン
    • 代表メッセージ
    • 会社概要
    • チーム
    • アクセス
  • 研究・技術
    • 糖尿病幹細胞とは
    • 糖尿病の完全寛解を目指す研究
    • Biozipcode™とは
    • 細胞標的化技術
    • 産学連携
      • 生命情報開拓講座(京都大学との産学共同研究)
      • 国内外の共同研究
    • パイプライン
      • 糖尿病根治治療候補
      • 糖尿病幹細胞バイオマーカー
      • Biozipcode™糖尿病細胞標的薬
      • がん細胞標的薬
      • 細胞標的化による組織再生
    • 研究実績
      • 主要論文
      • 特許・知的財産
      • 動画・講演・発表情報
  • パートナーの皆様へ
    • 製薬企業・研究機関の皆様へ
    • 共同研究
    • 技術ライセンス
    • 共同開発
    • 投資・資本提携
    • 資料ダウンロード
  • お問い合わせ
    • お問い合わせフォーム
    • 法務・ポリシー
    • プライバシーポリシー
    • サイトポリシー
    • Cookieポリシー
    • 医療・研究に関する免責事項
    • 利益相反・透明性方針
Go to Top